REPORT ID 6252

EMEA (Europe, Middle East and Africa) Ependymoma Drug Market Report 2017

Publish Date
25-Dec-17
Pages
105
Format
Electronic (PDF)

In this report, the EMEA Ependymoma Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Ependymoma Drug for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Ependymoma Drug market competition by top manufacturers/players, with Ependymoma Drug sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    Cavion LLC
    Advantagene Inc
    Amgen Inc
    Celgene Corp
    Eli Lilly and Company
    Millennium Pharmaceuticals Inc
    NewLink Genetics Corp
    Ono Pharmaceutical Co Ltd

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Abemaciclib
    Indoximod
    Afatinib Dimaleate
    Alisertib
    G-207
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Clinic
    Hospital
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Ependymoma Drug Market Report 2017
1 Ependymoma Drug Overview
    1.1 Product Overview and Scope of Ependymoma Drug
    1.2 Classification of Ependymoma Drug
        1.2.1 EMEA Ependymoma Drug Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Ependymoma Drug Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Abemaciclib
        1.2.4 Indoximod
        1.2.5 Afatinib Dimaleate
        1.2.6 Alisertib
        1.2.7 G-207
        1.2.8 Others
    1.3 EMEA Ependymoma Drug Market by Application/End Users
        1.3.1 EMEA Ependymoma Drug Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Clinic
        1.3.3 Hospital
        1.3.4 Others
    1.4 EMEA Ependymoma Drug Market by Region
        1.4.1 EMEA Ependymoma Drug Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Ependymoma Drug (2012-2022)
        1.5.1 EMEA Ependymoma Drug Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Ependymoma Drug Revenue and Growth Rate (2012-2022)

2 EMEA Ependymoma Drug Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Ependymoma Drug Market Competition by Players/Manufacturers
        2.1.1 EMEA Ependymoma Drug Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Ependymoma Drug Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Ependymoma Drug Sale Price by Players (2012-2017)
    2.2 EMEA Ependymoma Drug (Volume and Value) by Type/Product Category
        2.2.1 EMEA Ependymoma Drug Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Ependymoma Drug Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Ependymoma Drug Sale Price by Type (2012-2017)
    2.3 EMEA Ependymoma Drug (Volume) by Application
    2.4 EMEA Ependymoma Drug (Volume and Value) by Region
        2.4.1 EMEA Ependymoma Drug Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Ependymoma Drug Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Ependymoma Drug Sales Price by Region (2012-2017)

3 Europe Ependymoma Drug (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Ependymoma Drug Sales and Value (2012-2017)
        3.1.1 Europe Ependymoma Drug Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Ependymoma Drug Revenue and Growth Rate (2012-2017)
    3.2 Europe Ependymoma Drug Sales and Market Share by Type
    3.3 Europe Ependymoma Drug Sales and Market Share by Application
    3.4 Europe Ependymoma Drug Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Ependymoma Drug Sales Volume by Countries (2012-2017)
        3.4.2 Europe Ependymoma Drug Revenue by Countries (2012-2017)
        3.4.3 Germany Ependymoma Drug Sales and Growth Rate (2012-2017)
        3.4.4 France Ependymoma Drug Sales and Growth Rate (2012-2017)
        3.4.5 UK Ependymoma Drug Sales and Growth Rate (2012-2017)
        3.4.6 Russia Ependymoma Drug Sales and Growth Rate (2012-2017)
        3.4.7 Italy Ependymoma Drug Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Ependymoma Drug Sales and Growth Rate (2012-2017)

4 Middle East Ependymoma Drug (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Ependymoma Drug Sales and Value (2012-2017)
        4.1.1 Middle East Ependymoma Drug Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Ependymoma Drug Revenue and Growth Rate (2012-2017)
    4.2 Middle East Ependymoma Drug Sales and Market Share by Type
    4.3 Middle East Ependymoma Drug Sales and Market Share by Application
    4.4 Middle East Ependymoma Drug Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Ependymoma Drug Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Ependymoma Drug Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Ependymoma Drug Sales and Growth Rate (2012-2017)
        4.4.4 Israel Ependymoma Drug Sales and Growth Rate (2012-2017)
        4.4.5 UAE Ependymoma Drug Sales and Growth Rate (2012-2017)
        4.4.6 Iran Ependymoma Drug Sales and Growth Rate (2012-2017)

5 Africa Ependymoma Drug (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Ependymoma Drug Sales and Value (2012-2017)
        5.1.1 Africa Ependymoma Drug Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Ependymoma Drug Revenue and Growth Rate (2012-2017)
    5.2 Africa Ependymoma Drug Sales and Market Share by Type
    5.3 Africa Ependymoma Drug Sales and Market Share by Application
    5.4 Africa Ependymoma Drug Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Ependymoma Drug Sales Volume by Countries (2012-2017)
        5.4.2 Africa Ependymoma Drug Revenue by Countries (2012-2017)
        5.4.3 South Africa Ependymoma Drug Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Ependymoma Drug Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Ependymoma Drug Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Ependymoma Drug Sales and Growth Rate (2012-2017)

6 EMEA Ependymoma Drug Manufacturers/Players Profiles and Sales Data
    6.1 Boehringer Ingelheim GmbH
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Ependymoma Drug Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Boehringer Ingelheim GmbH Ependymoma Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Bristol-Myers Squibb Company
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Ependymoma Drug Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Bristol-Myers Squibb Company Ependymoma Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Cavion LLC
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Ependymoma Drug Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Cavion LLC Ependymoma Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Advantagene Inc
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Ependymoma Drug Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Advantagene Inc Ependymoma Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Amgen Inc
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Ependymoma Drug Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Amgen Inc Ependymoma Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Celgene Corp
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Ependymoma Drug Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Celgene Corp Ependymoma Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Eli Lilly and Company
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Ependymoma Drug Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Eli Lilly and Company Ependymoma Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Millennium Pharmaceuticals Inc
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Ependymoma Drug Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Millennium Pharmaceuticals Inc Ependymoma Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 NewLink Genetics Corp
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Ependymoma Drug Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 NewLink Genetics Corp Ependymoma Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Ono Pharmaceutical Co Ltd
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Ependymoma Drug Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Ono Pharmaceutical Co Ltd Ependymoma Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview

7 Ependymoma Drug Manufacturing Cost Analysis
    7.1 Ependymoma Drug Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Ependymoma Drug

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Ependymoma Drug Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Ependymoma Drug Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Ependymoma Drug Market Forecast (2017-2022)
    11.1 EMEA Ependymoma Drug Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Ependymoma Drug Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Ependymoma Drug Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Ependymoma Drug Price and Trend Forecast (2017-2022)
    11.2 EMEA Ependymoma Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Ependymoma Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Ependymoma Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Ependymoma Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Ependymoma Drug Sales Forecast by Type (2017-2022)
    11.7 EMEA Ependymoma Drug Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer